In vitro activity of imipenem/relebactam against Gram-negative ESKAPE pathogens isolated in 17 European countries: 2015 SMART surveillance programme

ConclusionsRelebactam restored susceptibility to imipenem for the majority of imipenem-non-susceptible isolates ofP. aeruginosa andK. pneumoniae tested as well as some isolates of imipenem-non-susceptibleEnterobacter spp. Based on our results, imipenem/relebactam appears to be a promising therapeutic option for treating patients with infections caused by antimicrobial-resistant Gram-negative bacilli.
Source: Journal of Antimicrobial Chemotherapy - Category: Microbiology Source Type: research